Nautica Enterprises, Inc. NAUT 深 滬
等待開盤 09-10 09:30:00 美东时间
0.67
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.67
- 總市值 8442.00万
- 52周最高 3.09
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.62
- 委 比 0.00%
- 總股本 1.26亿
- 歷史最高 12.38
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.62
- 每 手 1
- 風險率 0.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Revelation Biosciences (NASDAQ:REVB) stock moved upwards by 7.7% to $2...
今天 05:06
Nautilus Biotechnology to Participate in Upcoming September Investor Conferences
Nautilus Biotechnology, Inc. will participate in two investor conferences: Morgan Stanley's Global Healthcare Conference on September 8 and the Q3 Investor Summit Group Virtual Conference on September 16. Access live webcasts on their website at www.nautilus.bio.
08-27 12:00
Nautilus Biotechnology’s Q2 2025 Financial Highlights
Nautilus Biotechnolgy, Inc. ( ($NAUT) ) has released its Q2 earnings. Here is a...
08-01 13:25
Earnings Scheduled For July 31, 2025
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
Nautilus Biotechnology Enters Into An Agreement With The Allen Institute Focused On Investigating The Connection Between The Tau Protein And Neurodegenerative Conditions Such As Alzheimer's Disease
Allen Institute to employ Iterative Mapping, Nautilus' single-molecule proteomics method, to investigate connection between tau protein and Alzheimer's disease• Agreement links the organizations' next-generation
07-30 20:09
Nautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule Proteomics
<p>Nautilus Biotechnology and the Allen Institute have teamed up to investigate the connection between the tau protein and Alzheimer’s disease using Nautilus’ Iterative Mapping method. Their goal is to identify novel tau proteoforms, quantify their prevalence, and understand phosphorylation patterns that could predict disease progression. This collaboration leverages single-molecule proteomics to advance diagnostics and treatments for neurodegene...
07-30 12:00
Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025
Nautilus Biotechnology, Inc. will report second quarter 2025 financial results on July 31, 2025, before market open. A webcast conference call to discuss results and business developments will begin at 5:30 a.m. PT / 8:30 a.m. ET, available on www.nautilus.bio.
07-15 12:00
Nautilus Biotechnology Announces Board Restructuring
An update from Nautilus Biotechnolgy ( ($NAUT) ) is now available. Nautilus Bio...
06-24 05:01
NeuroPace Announces Promising NAUTILUS Study Results
NeuroPace ( ($NPCE) ) just unveiled an announcement. On May 27, 2025, NeuroPace...
05-27 20:29
NeuroPace Announces Preliminary Primary Endpoint 1-Yr Results Of Two-Year NAUTILUS Study Evaluating Safety And Effectiveness Of RNS System For Treatment Of Individuals With Drug-Resistant IGE
-- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy-- Study met the 12-week
05-27 20:12
